Metamizole Noridem (Metamizole Sodium Monohydrate)

Metamizole exerts its effect by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production, and by influencing endogenous opioid pathways. This dual action reduces pain signaling and helps reset the body’s temperature set‑point, providing both analgesic and antipyretic benefits.

The dosage of Metamizole Noridem is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Healthcare professionals calculate the appropriate amount and frequency according to local guidelines and individual therapeutic needs.

Safety data for Metamizole in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk, and it is generally avoided unless no safer alternatives are available.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike traditional NSAIDs, Metamizole has a distinct pyrazolone structure and a lower incidence of gastrointestinal irritation, but it carries a unique risk of severe blood dyscrasias like agranulocytosis. Clinicians may choose Metamizole when NSAIDs are contraindicated or when a rapid antipyretic effect is needed.

Metamizole Noridem should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. The product must remain sealed until reconstitution, and any unused portion should be discarded according to local pharmaceutical waste regulations.

The medication is supplied as a sterile powder that is reconstituted with a suitable diluent. It is then administered by intramuscular or intravenous injection under the supervision of qualified healthcare personnel, following aseptic technique and appropriate dosing calculations.

The most critical safety concerns include agranulocytosis, which can lead to severe infections, and life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt recognition of symptoms and immediate medical intervention are essential to mitigate these risks.

Metamizole is contraindicated in patients with known hypersensitivity to pyrazolones, a history of agranulocytosis or other severe blood disorders, and in individuals with severe hepatic or renal impairment unless closely monitored. It should also be avoided in pregnant or breastfeeding women unless the therapeutic benefit outweighs potential risks.